SIPA1L2

Summary

SIPA1L2 (signal induced proliferation associated 1 like 2, HGNC:23800) is a protein-coding gene on chromosome 1q42.2, encoding Signal-induced proliferation-associated 1-like protein 2 (Q9P2F8).

This gene encodes a member of the signal-induced proliferation-associated 1 like family. Members of this family contain a GTPase activating domain, a PDZ domain and a C-terminal coiled-coil domain with a leucine zipper. A similar protein in rat acts as a GTPases for the small GTPase Rap.

Source: NCBI Gene 57568 — RefSeq curated summary.

At a glance

• GWAS associations: 15
• Clinical variants (ClinVar): 285 total
• MANE Select transcript: NM_020808

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23800
Approved symbol	SIPA1L2
Name	signal induced proliferation associated 1 like 2
Location	1q42.2
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1389, SPAR2
Ensembl gene	ENSG00000116991
Ensembl biotype	protein_coding
OMIM	611609
Entrez	57568

Gene structure

Transcript identifiers

Ensembl transcripts: 47 — 43 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000308942, ENST00000366630, ENST00000486472, ENST00000494056, ENST00000495863, ENST00000674635, ENST00000674749, ENST00000674801, ENST00000675407, ENST00000675685, ENST00000676213, ENST00000883504, ENST00000883505, ENST00000883506, ENST00000883507, ENST00000883508, ENST00000883509, ENST00000883510, ENST00000930079, ENST00000930080, ENST00000930081, ENST00000930082, ENST00000930083, ENST00000930084, ENST00000930085, ENST00000964474, ENST00000964475, ENST00000964476, ENST00000964477, ENST00000964478, ENST00000964479, ENST00000964480, ENST00000964481, ENST00000964482, ENST00000964483, ENST00000964484, ENST00000964485, ENST00000964486, ENST00000964487, ENST00000964488, ENST00000964489, ENST00000964490, ENST00000964491, ENST00000964492, ENST00000964493, ENST00000964494, ENST00000964495

RefSeq mRNA: 2 — MANE Select: NM_020808 NM_001377488, NM_020808

CCDS: CCDS41474, CCDS91174

Canonical transcript exons

ENST00000674635 — 23 exons

Exon	Start	End
ENSE00000793231	232415494	232415625
ENSE00000793232	232425589	232425808
ENSE00000805300	232428411	232428564
ENSE00000805303	232460887	232461161
ENSE00000921398	232402392	232402473
ENSE00000921399	232403448	232403571
ENSE00000921400	232404125	232404178
ENSE00000921401	232432247	232432471
ENSE00000921402	232439108	232439496
ENSE00000921408	232483792	232483966
ENSE00000921409	232490874	232491062
ENSE00001176131	232441291	232441394
ENSE00001176138	232441768	232441868
ENSE00001176143	232443602	232443685
ENSE00001176150	232445529	232445786
ENSE00001176160	232464840	232465416
ENSE00001442210	232397965	232399273
ENSE00001442211	232513857	232515608
ENSE00001796126	232479627	232479730
ENSE00002220003	232471371	232471528
ENSE00003560550	232493527	232493660
ENSE00003900808	232574174	232574222
ENSE00003901320	232629869	232630133

Expression profiles

Bgee: expression breadth ubiquitous, 254 present calls, max score 98.81.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.8887 / max 98.9565, expressed in 1035 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
18010	4.4163	999
201993	0.4392	263
18009	0.0332	10

Top tissues by expression

258 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left ventricle myocardium	UBERON:0006566	98.81	gold quality
cardiac muscle of right atrium	UBERON:0003379	98.56	gold quality
pons	UBERON:0000988	97.59	gold quality
decidua	UBERON:0002450	97.57	gold quality
heart right ventricle	UBERON:0002080	97.40	gold quality
myocardium	UBERON:0002349	97.09	gold quality
lateral nuclear group of thalamus	UBERON:0002736	96.41	gold quality
buccal mucosa cell	CL:0002336	96.20	gold quality
middle temporal gyrus	UBERON:0002771	95.75	gold quality
sural nerve	UBERON:0015488	95.75	gold quality
substantia nigra pars compacta	UBERON:0001965	94.99	gold quality
substantia nigra pars reticulata	UBERON:0001966	94.61	gold quality
endothelial cell	CL:0000115	94.27	gold quality
trigeminal ganglion	UBERON:0001675	93.88	gold quality
epithelial cell of pancreas	CL:0000083	93.77	gold quality
tibialis anterior	UBERON:0001385	93.55	gold quality
Brodmann (1909) area 23	UBERON:0013554	93.41	gold quality
dorsal root ganglion	UBERON:0000044	93.26	gold quality
visceral pleura	UBERON:0002401	93.06	gold quality
secondary oocyte	CL:0000655	92.97	gold quality
lower esophagus mucosa	UBERON:0035834	92.81	gold quality
cardiac ventricle	UBERON:0002082	91.86	gold quality
esophagus squamous epithelium	UBERON:0006920	91.85	gold quality
cardiac atrium	UBERON:0002081	91.84	gold quality
heart left ventricle	UBERON:0002084	91.71	gold quality
tendon of biceps brachii	UBERON:0008188	91.65	gold quality
oocyte	CL:0000023	91.64	gold quality
Brodmann (1909) area 46	UBERON:0006483	91.58	gold quality
superior vestibular nucleus	UBERON:0007227	91.55	gold quality
tibial nerve	UBERON:0001323	91.43	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	24.00
E-ENAD-27	yes	10.31
E-ANND-3	yes	5.87
E-MTAB-7303	no	197.14

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

146 targeting SIPA1L2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4692	100.00	67.32	2066
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-493-5P	99.96	72.47	2382
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-3143	99.93	71.96	3104

Literature-anchored findings (GeneRIF, showing 2)

• Our results suggest that rs329648 is associated with risk of developing PD in the Han Chinese population. Our findings should be verified in further studies, and they highlight the need for functional studies of MIR4697. (PMID:28380328)
• SIPA1L2 is a potential genetic modifier of CMT1A phenotypic expressions. (PMID:30706531)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	sipa1l2	ENSDARG00000061640
mus_musculus	Sipa1l2	ENSMUSG00000001995
rattus_norvegicus	Sipa1l2	ENSRNOG00000019791
drosophila_melanogaster	RapGAP1	FBGN0264895
caenorhabditis_elegans		WBGENE00018734

Paralogs (6): RAP1GAP (ENSG00000076864), SIPA1L3 (ENSG00000105738), RAP1GAP2 (ENSG00000132359), GARNL3 (ENSG00000136895), SIPA1L1 (ENSG00000197555), SIPA1 (ENSG00000213445)

Protein

Protein identifiers

Signal-induced proliferation-associated 1-like protein 2 — Q9P2F8 (reviewed: Q9P2F8)

All UniProt accessions (4): A0A6Q8PFQ0, A0A6Q8PGD5, A0A6Q8PH54, Q9P2F8

Isoforms (2)

UniProt ID	Names	Canonical?
Q9P2F8-1	1	yes
Q9P2F8-2	2

RefSeq proteins (2): NP_001364417, NP_065859* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000331	Rap/Ran_GAP_dom	Domain
IPR001478	PDZ	Domain
IPR021818	SIPA1L_C	Domain
IPR035974	Rap/Ran-GAP_sf	Homologous_superfamily
IPR036034	PDZ_sf	Homologous_superfamily
IPR050989	Rap1_Ran_GAP	Family

Pfam: PF00595, PF02145, PF11881, PF21022

UniProt features (42 total): modified residue 12, compositionally biased region 10, region of interest 5, sequence variant 5, splice variant 3, sequence conflict 3, domain 2, chain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9P2F8-F1	56.59	0.24

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (12): 148, 379, 383, 1029, 1244, 1461, 1472, 1478, 1488, 1549, 1552, 1591

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 192 (showing top): WHITEHURST_PACLITAXEL_SENSITIVITY, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, PEREZ_TP63_TARGETS, GOZGIT_ESR1_TARGETS_DN, GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, GTTAAAG_MIR302B, ATGTTAA_MIR302C, WANG_LMO4_TARGETS_DN, KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, PEREZ_TP53_AND_TP63_TARGETS, CTTTGTA_MIR524, MODULE_207, GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION

GO Biological Process (3): regulation of small GTPase mediated signal transduction (GO:0051056), presynaptic signal transduction (GO:0098928), biological_process (GO:0008150)

GO Molecular Function (2): GTPase activator activity (GO:0005096), protein binding (GO:0005515)

GO Cellular Component (3): cytoplasm (GO:0005737), glutamatergic synapse (GO:0098978), cellular_component (GO:0005575)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
small GTPase-mediated signal transduction	1
regulation of intracellular signal transduction	1
signal transduction	1
GTPase activity	1
enzyme activator activity	1
GTPase regulator activity	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
synapse	1

Protein interactions and networks

STRING

778 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SIPA1L2	SNAPIN	O95295	614
SIPA1L2	PRR35	P0CG20	576
SIPA1L2	DDRGK1	Q96HY6	567
SIPA1L2	VPS13C	Q709C8	544
SIPA1L2	KBTBD12	Q3ZCT8	523
SIPA1L2	RIT2	Q99578	507
SIPA1L2	RRP36	Q96EU6	493
SIPA1L2	SPMIP7	A4D263	472
SIPA1L2	KLHDC8B	Q8IXV7	472
SIPA1L2	TOGARAM1	Q9Y4F4	469
SIPA1L2	IHO1	Q8IYA8	455
SIPA1L2	KCNG3	Q8TAE7	450
SIPA1L2	VWC2	Q2TAL6	445
SIPA1L2	LZTS3	O60299	443
SIPA1L2	PKDCC	Q504Y2	437

IntAct

525 interactions, top by confidence:

A	B	Type	Score
YWHAG	BLTP3B	psi-mi:“MI:2364”(proximity)	0.640
PRG2	YPEL5	psi-mi:“MI:0914”(association)	0.640
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
E	SIPA1L2	psi-mi:“MI:0915”(physical association)	0.610
YWHAB	BLTP3B	psi-mi:“MI:2364”(proximity)	0.610
E	SIPA1L2	psi-mi:“MI:0407”(direct interaction)	0.610
SIPA1L2	E6	psi-mi:“MI:0915”(physical association)	0.590
E6	SIPA1L2	psi-mi:“MI:0407”(direct interaction)	0.590
YWHAH	BLTP3B	psi-mi:“MI:2364”(proximity)	0.570
YWHAG	SHTN1	psi-mi:“MI:0914”(association)	0.560
TSPYL1	GPC3	psi-mi:“MI:0914”(association)	0.530
YWHAQ	IGLC7	psi-mi:“MI:0914”(association)	0.530
YWHAB	SHTN1	psi-mi:“MI:0914”(association)	0.530
YWHAE	SHTN1	psi-mi:“MI:0914”(association)	0.530
YWHAZ	SHTN1	psi-mi:“MI:0914”(association)	0.530
YWHAZ	BLTP3B	psi-mi:“MI:0914”(association)	0.530
DYRK1B	BMAL1	psi-mi:“MI:0914”(association)	0.530
GNG4	SIPA1L2	psi-mi:“MI:0407”(direct interaction)	0.440
CREBBP	SIPA1L2	psi-mi:“MI:0407”(direct interaction)	0.440
E6	SIPA1L2	psi-mi:“MI:0407”(direct interaction)	0.440
Tax	SIPA1L2	psi-mi:“MI:0407”(direct interaction)	0.440
NET1	SIPA1L2	psi-mi:“MI:0407”(direct interaction)	0.440
PTEN	SIPA1L2	psi-mi:“MI:0407”(direct interaction)	0.440
RPS6KA1	SIPA1L2	psi-mi:“MI:0407”(direct interaction)	0.440
E	SIPA1L2	psi-mi:“MI:0407”(direct interaction)	0.440
GP1	SIPA1L2	psi-mi:“MI:0407”(direct interaction)	0.440
ABCA1	SIPA1L2	psi-mi:“MI:0407”(direct interaction)	0.440
ABRAXAS2	SIPA1L2	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (173): SIPA1L2 (Two-hybrid), SIPA1L2 (Affinity Capture-MS), SIPA1L2 (Affinity Capture-MS), SIPA1L2 (Affinity Capture-MS), SIPA1L2 (Proximity Label-MS), SIPA1L2 (Proximity Label-MS), SIPA1L2 (Proximity Label-MS), SIPA1L2 (Proximity Label-MS), SIPA1L2 (Proximity Label-MS), SIPA1L2 (Proximity Label-MS), SIPA1L2 (Affinity Capture-MS), SIPA1L2 (Affinity Capture-MS), SIPA1L2 (Affinity Capture-MS), SIPA1L2 (Affinity Capture-MS), SIPA1L2 (Affinity Capture-MS)

ESM2 similar proteins: A1A5R8, A8KBE0, B4F6Q9, E7FA21, O43166, P53804, P62287, P62289, P62290, P62291, P62292, P62293, P62294, Q06190, Q08AX9, Q0VA42, Q12923, Q13829, Q3UMB5, Q5F3E8, Q5JCS6, Q5RA75, Q5RBH4, Q5TB30, Q5XKL5, Q5ZIX8, Q65Z40, Q68FF0, Q6DJS0, Q6GQJ2, Q6IE81, Q6ING4, Q6IRN6, Q6NPP4, Q6NSI8, Q6PUR7, Q7Z5K2, Q7ZXG4, Q8C0T5, Q8CIG0

Diamond homologs: A2ALS5, A5PF44, G3X9J0, O35412, O43166, O60292, P46062, P47736, P49815, P49816, Q3V0G7, Q54EH3, Q55AN8, Q5JCS6, Q5SVL6, Q5VVW2, Q5ZJY3, Q5ZMV8, Q61037, Q684P5, Q75J96, Q80TE4, Q8C0T5, Q96FS4, Q9P2F8, Q2PPJ7, Q9UUG9, A3KGS3, P86411, Q6GYQ0, Q8BUL6, Q9HB21, Q54TK4, Q9VB98, O55007, Q6GYP7, Q54SS8

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 178 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	7	47.2×	8e-09
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	7	41.6×	2e-08
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	41.6×	2e-08
Activation of BH3-only proteins	7	30.8×	1e-07
RHO GTPases activate PKNs	7	19.6×	4e-06
Intrinsic Pathway for Apoptosis	7	18.1×	5e-06
FOXO-mediated transcription	6	17.8×	4e-05
Transcriptional and post-translational regulation of MITF-M expression and activity	8	12.6×	1e-05

GO biological processes:

GO term	Partners	Fold	FDR
intracellular protein localization	10	6.6×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

285 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	240
Likely benign	13
Benign	10

Top pathogenic / likely-pathogenic (0)

SpliceAI

4049 predictions. Top by Δscore:

Variant	Effect	Δscore
1:232402379:T:TA	donor_gain	1.0000
1:232402387:ATTAC:A	donor_loss	1.0000
1:232402388:TTACC:T	donor_loss	1.0000
1:232402389:TACCT:T	donor_loss	1.0000
1:232402391:C:CT	donor_loss	1.0000
1:232402394:T:A	donor_gain	1.0000
1:232403572:C:CC	acceptor_gain	1.0000
1:232415488:CTTTA:C	donor_loss	1.0000
1:232415489:TTTA:T	donor_loss	1.0000
1:232415490:TTA:T	donor_loss	1.0000
1:232415491:TACC:T	donor_loss	1.0000
1:232415621:CTCAT:C	acceptor_gain	1.0000
1:232415622:TCAT:T	acceptor_gain	1.0000
1:232415623:CAT:C	acceptor_gain	1.0000
1:232415623:CATC:C	acceptor_gain	1.0000
1:232415625:TC:T	acceptor_loss	1.0000
1:232415626:C:CC	acceptor_gain	1.0000
1:232425587:A:AC	donor_gain	1.0000
1:232425588:C:CC	donor_gain	1.0000
1:232425588:CTTCT:C	donor_gain	1.0000
1:232425796:C:T	acceptor_gain	1.0000
1:232428406:CTAA:C	donor_loss	1.0000
1:232428407:TAA:T	donor_loss	1.0000
1:232428408:AACCT:A	donor_loss	1.0000
1:232428409:A:AG	donor_loss	1.0000
1:232428561:CATC:C	acceptor_gain	1.0000
1:232428565:C:CC	acceptor_gain	1.0000
1:232439102:GCTTA:G	donor_loss	1.0000
1:232439103:CTTA:C	donor_loss	1.0000
1:232439104:TTA:T	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000001614 (1:232614767 AG>A), RS1000006790 (1:232447231 T>C), RS1000016017 (1:232573904 G>A), RS1000035190 (1:232447424 A>C), RS1000056111 (1:232569168 T>C), RS1000077031 (1:232534839 CCT>C), RS1000093375 (1:232575966 G>A), RS1000150365 (1:232478707 T>C), RS1000160385 (1:232474256 G>A), RS1000173515 (1:232609190 T>C), RS1000175947 (1:232467498 G>A,C), RS1000179553 (1:232505657 C>T), RS1000210677 (1:232625837 T>C), RS1000224110 (1:232608919 A>G), RS1000230954 (1:232563309 T>C)

Disease associations

OMIM: gene MIM:611609 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

15 associations (top):

Study	Trait	p-value
GCST000763_1	Immunoglobulin A	1.000000e-06
GCST002361_17	Smooth-surface caries	8.000000e-06
GCST002401_1	Post-traumatic stress disorder	8.000000e-06
GCST002544_12	Parkinson’s disease	5.000000e-10
GCST004902_41	Parkinson’s disease	8.000000e-13
GCST007205_7	Schizophrenia	1.000000e-06
GCST007304_1	Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A	6.000000e-08
GCST009325_85	Parkinson’s disease or first degree relation to individual with Parkinson’s disease	7.000000e-17
GCST010320_119	PR interval	3.000000e-14
GCST010321_183	PR interval	3.000000e-15
GCST010989_191	Body size at age 10	7.000000e-09
GCST010991_27	Parkinson’s disease	2.000000e-07
GCST011696_5	Alzheimer’s disease	6.000000e-07
GCST012307_3	Bipolar disorder x sex interaction	2.000000e-06
GCST90000047_22	Age at first sexual intercourse	2.000000e-08

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004747	protein measurement
EFO:0004462	PR interval
EFO:0009819	comparative body size at age 10, self-reported
EFO:0008343	sex interaction measurement
EFO:0009749	age at first sexual intercourse measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

72 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression, decreases methylation	4
Valproic Acid	decreases expression, increases expression	4
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression, increases expression	3
sodium arsenite	decreases expression, increases expression	2
potassium chromate(VI)	affects cotreatment, decreases expression	2
mercuric bromide	affects cotreatment, increases expression	2
(+)-JQ1 compound	increases expression	2
Benzo(a)pyrene	increases expression	2
Cisplatin	affects expression	2
Estradiol	affects cotreatment, increases expression, decreases reaction	2
Ethinyl Estradiol	affects expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tretinoin	decreases expression, increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
mivebresib	increases expression	1
2,4,6-tribromophenol	decreases expression	1
chloroacetaldehyde	decreases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
2,5,2’,5’-tetrachlorobiphenyl	increases expression	1
decabromobiphenyl ether	decreases expression	1
trichostatin A	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
cobaltous chloride	decreases expression	1
tetrabromobisphenol A	decreases expression	1
diallyl trisulfide	decreases expression	1
beta-methylcholine	affects expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.